Further studies in breast cancer xenograft mouse models are necessary to compare in vivo antitumor activity and in vivo persistence between anti-MUC-1 CAR T cells with a 4-1BB or CD-28 endosignaling domain. This evidence concerns the gene CD28 and breast cancer.